Literature DB >> 8817836

Immunohistochemical characterization of hemangiopericytomas and other spindle cell tumors in the dog.

J Pérez1, M J Bautista, E Rollón, F C de Lara, L Carrasco, J Martin de las Mulas.   

Abstract

The immunohistochemical expression of muscle actin has been studied in 45 canine hemangiopericytomas (CHP) using a monoclonal antibody (HHF35) and formalin-fixed, paraffin-embedded specimens. The distribution of vimentin, desmin, cytokeratins, lysozyme, factor VIII-related antigen, S-100 protein, and glial fibrillary acidic protein was studied both in CHP and in some canine soft-tissue neoplasms (seven fibrosarcomas, seven benign schwannomas, seven benign fibrous histiocytomas, and six leiomyosarcomas) used as controls for differential diagnosis. All CHP and control tumors expressed vimentin. Twenty-three CHP expressed muscle actin, whereas all control tumors analyzed were muscle actin-negative, with the exception of leiomyosarcomas. Among muscle actin- and vimentin-positive CHP, one case could be reclassified as leiomyosarcoma because it was desmin-positive, two cases expressed lysozyme, and nine cases expressed S-100 protein. Among muscle actin-negative and vimentin-positive CHP, seven expressed S-100 protein. In addition, S-100 protein was detected in five schwannomas. All CHP and control tumors analyzed were negative for cytokeratins, factor VIII-related antigen, and glial fibrillary acidic protein. Our results support the hypothesis of a pericytic origin of CHP, and suggest that muscle actin, desmin, vimentin, and lysozyme could be useful for the differential diagnosis of canine spindle cell tumors, but not all these neoplasms can be identified with these tumor tissue markers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8817836     DOI: 10.1177/030098589603300404

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  8 in total

1.  Primary cardiac spindle cell tumor in a dog.

Authors:  Midori G Asakawa; Marisa K Ames; Yongbaek Kim
Journal:  Can Vet J       Date:  2013-07       Impact factor: 1.008

2.  Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics.

Authors:  Jen-Tsan Chi; Donald E Thrall; Chen Jiang; Stacey Snyder; Diane Fels; Chelsea Landon; Linda McCall; Lan Lan; Marlene Hauck; James R MacFall; Benjamin L Viglianti; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2011-02-03       Impact factor: 12.531

3.  Retrospective immunohistochemical investigation of suspected non-visceral leiomyosarcoma in dogs.

Authors:  Rachel V Brady; Robert B Rebhun; Katherine A Skorupski; Jenna H Burton; Sami Al-Nadaf; Eunju Choi; Jennifer L Willcox
Journal:  J Vet Diagn Invest       Date:  2022-03-15       Impact factor: 1.569

Review 4.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

5.  Morphological characterisation of portal myofibroblasts and hepatic stellate cells in the normal dog liver.

Authors:  Jooske Ijzer; Tania Roskams; Ronald F Molenbeek; Ton Ultee; Louis C Penning; Jan Rothuizen; Ted S G A M van den Ingh
Journal:  Comp Hepatol       Date:  2006-11-16

6.  Hemangiopericytoma in a young dog: Evaluation of histopathological and immunohistochemical features.

Authors:  Fatemeh Namazi; Mohammad Abbaszadeh Hasiri; Ahmad Oryan; Ali Moshiri
Journal:  Vet Res Forum       Date:  2014       Impact factor: 1.054

7.  Subcutaneous soft tissue sarcoma with rhabdoid features in a dog.

Authors:  Ayako Sayama; Keiko Okado; Masako Imaoka; Yusuke Yokouchi; Toshimasa Jindo; Wataru Takasaki
Journal:  J Toxicol Pathol       Date:  2014-02-05       Impact factor: 1.628

8.  Metastatic intraocular hemangiopericytoma in a dog.

Authors:  Jonathan D Pucket; Rachel A Allbaugh; Mary L Higginbotham; Amy J Rankin; Leandro Teixeira
Journal:  Open Vet J       Date:  2017-05-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.